TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT05236114: GEMINI-NSCLC: NSCLC Biomarker Study

Sponsor: Tempus AI · Phase: PHASE2 · Area: ONCOLOGY · Target Enrollment: 1200 pts

Competing Trials Overlap

14 Active Trials

Excess Burn Exposure

$11,503,800

Rescue Site Savings

+$7,576,800

Unlock Full NCT05236114 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT05236114 Rescue Dossier →